Advances in Biomaterials for Drug Delivery

Owen S Fenton; Katy N Olafson; Padmini S Pillai; Michael J Mitchell; Robert Langer

doi:10.1002/adma.201705328

Advances in Biomaterials for Drug Delivery

Adv Mater. 2018 May 7:e1705328. doi: 10.1002/adma.201705328. Online ahead of print.

Authors

Owen S Fenton^{1

2}, Katy N Olafson^{1

2}, Padmini S Pillai^{1

2}, Michael J Mitchell³, Robert Langer^{1

2

4}

Affiliations

¹ Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02142, USA.
² Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02142, USA.
³ Department of Bioengineering, University of Pennsylvania, School of Engineering and Applied Science, Philadelphia, PA, 19104, USA.
⁴ Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.

Abstract

Advances in biomaterials for drug delivery are enabling significant progress in biology and medicine. Multidisciplinary collaborations between physical scientists, engineers, biologists, and clinicians generate innovative strategies and materials to treat a range of diseases. Specifically, recent advances include major breakthroughs in materials for cancer immunotherapy, autoimmune diseases, and genome editing. Here, strategies for the design and implementation of biomaterials for drug delivery are reviewed. A brief history of the biomaterials field is first established, and then commentary on RNA delivery, responsive materials development, and immunomodulation are provided. Current challenges associated with these areas as well as opportunities to address long-standing problems in biology and medicine are discussed throughout.

Keywords: biomaterials; drug delivery; immune therapy; nanomedicine; polymers.

Publication types

Review

Abstract

Publication types

Grants and funding